Clinical Trial Update: Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects [Phase 3]

View source ↗

Summary

A Phase 3 trial update reporting on the efficacy, immunogenicity, and safety of GSK's HPV vaccine (GSK 580299) in healthy Chinese female subjects, with complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Human Papillomavirus Infection
• Papillomavirus Infections

Drugs mentioned

• HPV GSK 580299 vaccine (HPV vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Papillomavirus | Phase 3 | Status: COMPLETED | Results posted: 2012-05-10